Embed Size (px)
Citation preview
PresidentProf. Alberto BosiHematology Department AOU Careggi University of Florence
scientific secretAriAtelisabetta Antonioli, Valentina carrai, stefania ciolli, Giacomo Gianfaldoni, Luigi rigacci, Barbara scappiniHematology Department AOU Careggi University of Florence
MeetinG LocAtionAula Magna - 1° Piano Rettorato University of Florence P.zza San Marco 4 - Firenze
ecM / cMe AccreditAtioneCM has been required for the following professional figures: Hematologists, oncologists,Biologists, Pharmacists, Biomedical Laboratory technicians and nurses
registration is free of charges and has to be done online from the website www.mitcongressi.it section: IX INTeRNATIONAL FLOReNCe MeeTING ON HeMATOLOGYtArGet tHerAPY
Provider and Logistic secretariat
Mi&t srl Viale Carducci, 50 - 40125 BolognaTel. 051 220427 - 335 [email protected] - www.mitcongressi.it
TARGET THERAPYAPRil 20-21, 2017
President: Prof. AlbERTo bosi
SILVeR
GOLD
UNReSTRICTeD GRANT BY
9.00 Authorities and Introduction A. Bosi
SeSSION 1 cHronic MYeLoid LeUKeMiA Chairs G. Specchia, F. Pane 9.15 optimizing frontline tKi G. Saglio 9.45 treatment switch P. E. Westerweel10.15 tKi and selected complications M. Bocchia10.45 treatment free remission M. Baccarani 11.15 Discussion
11.30 Coffee Break
SeSSION 2 non neoPLAstic diseAses Chairs V. De Stefano, G. Castaman11.45 PnH Monoclonal Antibodies today and perspectives R. Notaro12.05 Gaucher: new diagnostic and therapeutic aspects M. D. Cappellini12.25 Primitive immune cytopenias W. Barcellini12.45 secondary immune cytopenias C. Dearden13.05 Discussion
13.20 Light Lunch
SeSSION 3 AcUte LeUKeMiAs Chairs A. Rambaldi, S. Amadori14.30 tKi in Ph1+ ALL R. Foa15.00 the optimal target in B-ALL N. Gokbuget15.30 fLt-3 inhibitors in AML J. Sierra
16.00 Coffee Break
16.15 chimeric Antigen receptor (cAr) t therapy in leukemias M. Schmitt16.45 retinoic Acid and Arsenic trioxide F. Lo Coco17.15 Discussion
SeSSION 4 MULtiPLe MYeLoMA Chairs M. Petrini, M. Gobbi 9.00 check-point inhibitors M. Boccadoro 9.30 Monoclonal antibodies P. Moreau10.00 Proteasome inhibitors A. Corso10.30 immunomodulants Agents N. Lehners11.00 Discussion
11.15 Coffee Break
SeSSION 5 cHronic LYMPHocYtic LeUKeMiA Chairs A. Cuneo, M. Musso11.30 Monoclonal Antibodies P. Cramer12.00 Pi3K inhibitors P. Ghia12.30 BtK inhibitors M. Spaargaren13.00 Bcl-2 inhibitors D. Rossi13.30 Discussion
13.45 Light Lunch
SeSSION 6 non HodGKin LYMPHoMAs Chairs R. Fanin, G. Semenzato14.45 Monoclonal Antibodies (unconjugated and conjugated) G. Gaidano15.15 immunomodulants Agents and other inhibitors A. Davies15.45 cAr-t therapy: clinical Protocols N. Biagi 16.15 Discussion
16.30 Coffee Break
SeSSION 7 HodGKin LYMPHoMAs Chairs G. La Nasa, A. Olivieri16.45 Monoclonal Antibodies F. Keil17.15 check-point inhibitors and other inhibitors L. Rigacci17.45 Bcl-2 expression in patients with classical Hd A. Cuccaro18.15 Discussion
18.30 Summing up and Conclusions A. Bosi
Sergio Amadori ROMeMichele Baccarani BOLOGNAWilma Barcellini MILANNicola Biagi MONzAMario Boccadoro TURINMonica Bocchia SIeNAAlberto Bosi FLOReNCeMaria D. Cappellini MILANGiancarlo Castaman FLOReNCe Alessandro Corso PAVIAPaula Cramer COLOGNe- DAnnarosa Cuccaro ROMeAntonio Cuneo FeRRARAAndrew Davies SOUTHAMPTON - UKValerio De Stefano ROMeClaire Dearden LONDON - UKRenato Fanin UDINeRobin Foa ROMeGianluca Gaidano NOVARAPaolo Ghia MILANMarco Gobbi GeNOANicola Gokbuget FRANKFURT - DFelix Keil WIeN -AGiorgio La Nasa CAGLIARINicola Lehners HeIDeLBeRG - DFrancesco Lo Coco ROMePhilippe Moreau NANTeS - FMaurizio Musso PALeRMORosario Notaro FLOReNCe Attilio Olivieri ANCONAFabrizio Pane NAPLeSMario Petrini PISAAlessandro Rambaldi BeRGAMOLuigi Rigacci FLOReNCe Davide Rossi BeLLINzONA -CHGiuseppe Saglio TURINMichael Schmitt HeIDeLBeRG - DGiampietro Semenzato PADUAJorge Sierra BARCeLONA - eMarcel Spaargaren AMSTeRDAM - NLGiorgina Specchia BARIPeter e. Westerweel DORDReCHT - NL
APriL 20, 2017
APriL 21, 2017
fAcU
LtY
